{"entity":{"id":"fcgr3a","kind":"target","name":"FCGR3A","aka":["Fc gamma receptor IIIa","Low affinity immunoglobulin gamma Fc region receptor III-A","CD16","CD16a","FcgammaRIIIa","FcGRIIIA","FCGR3","FCG3"],"tldr":"FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.","summary":"Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger.\n\nCIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Trastuzumab.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3619","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3619"},{"label":"UniProt P08637","url":"https://www.uniprot.org/uniprotkb/P08637/entry"},{"label":"NCBI Gene 2214","url":"https://www.ncbi.nlm.nih.gov/gene/2214"},{"label":"Ensembl ENSG00000203747","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000203747"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["breast-cancer","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["complement-in-cancer","nk-cell-recognition"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FCGR3A","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:3619","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3619","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P08637","url":"https://www.uniprot.org/uniprotkb/P08637/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene FCGR3A","url":"https://civicdb.org/features/1844","note":"2 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer, HER2 Positive Breast Cancer (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FCGR3A: RNA tissue enhanced (lung 196 nTPM, lymphoid tissue 285 nTPM); blood lineage lineage enriched (monocytes 4,107 nTPM); high antibody staining in 4 normal tissues; highest cancer staining ovarian cancer (1 of 10 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas FCGR3A tissue","url":"https://www.proteinatlas.org/ENSG00000203747-FCGR3A/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000203747 associations","url":"https://platform.opentargets.org/target/ENSG00000203747/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3619","ensembl":"ENSG00000203747","uniprot":"P08637","entrez":"2214","firstDescribed":1989,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Ravetch J.V. et al, J. Exp. Med, 1989, \"Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2526846/","biology":"Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger. Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC. Location: Cell membrane; Secreted (UniProt). Locus 1q23.3 (HGNC).","whereFound":["Breast cancer: CIViC evidence names this disease","HER2-positive breast cancer: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/fcgr3a/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"pathway":[{"id":"complement-in-cancer","kind":"pathway","name":"Complement in cancer","route":"/pathways/complement-in-cancer/"},{"id":"nk-cell-recognition","kind":"pathway","name":"NK-cell recognition: missing self & stress ligands","route":"/pathways/nk-cell-recognition/"}]}}